The tiny molecule that flips prostate cancer back to being treatable

Fred Hutch researchers discovered that a single transfer RNA — a small helper molecule cells use to build proteins — can determine whether prostate cancer stays sensitive to therapy or morphs into an aggressive, drug-resistant form. Restoring levels of this molecule (called tRNAArg(UCU)-1) in resistant cancer cells and lab models effectively re-sensitized tumors to existing androgen-receptor drugs — a potential route to reverse drug resistance. It opens a brand-new chapter of cancer biology: transfer RNAs as active controllers, not bystanders.